New Therapeutics for Traumatic Brain Injury

New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration explores traumatic brain injury (TBI), a major cause of death and disability throughout the world. The delayed nature of the secondary injury phase suggests that there is a therapeutic window for pharmacological interventions or other approaches to prevent progressive tissue damage and improve functional outcomes. It is now apparent that therapeutic interventions should entail both protective and repair/regeneration strategies depending on the phase of brain injury. This book describes emerging experimental strategies for the treatment of TBI, including new anti-inflammatory or anti-apoptotic therapeutics that limit brain damage, and novel or repurposed drugs that enhance repair or regeneration of the brain after injury.
- Comprehensive overview of basic approaches and translational development of new therapies for TBI
- Edited by a prominent TBI researcher that includes contributions by leading global researchers in the field
- Presents a great resource for researchers and practitioners to learn more about the many evolving preclinical studies and clinical trials currently underway, and the challenges of bringing translational studies in TBI to the clinic

Part I. Interventional Therapies for TBI Previously or Currently in Phase 3 Clinical Trials1. Why Did the Phase III Clinical Trials for Progesterone in TBI Fail? An Analysis of Three Potentially Critical Factors2. Hypothermia for Traumatic Brain Injury: Current Evidence and Future Directions3. The Future of TBI: Hyperbaric Oxygen as a Primary Therapeutic Approach Part II. Repurposing FDA Approved Drugs for TBI Treatment4. Erythropoietin and Its Derivatives: Mechanisms of Neuroprotection and Challenges in Clinical Translation5. Atorvastatin in the Treatment of Traumatic Brain Injury6. The Application of Glibenclamide in Traumatic Brain Injury7. Perispinal Etanercept for Traumatic Brain Injury Part III. Interventional Drugs for TBI in Phase 1-2 Clinical Trials8. Nitric Oxide Synthase Inhibitors in Traumatic Brain Injury9. Management of Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury Part IV. Interventional Drugs for TBI in Preclinical Development10. The Use of Estrogen for the Treatment of Traumatic Brain Injury11. Voltage-Gated Calcium Channel Blockers for the Treatment of Traumatic Brain Injury12. 5-Lipoxygenase-Activating Protein Inhibitors: Promising Drugs for Treating Acute and Chronic Neuroinflammation Following Brain Injury13. Carbonyl Scavenging as an Antioxidant Neuroprotective Strategy for Acute Traumatic Brain Injury14. TrkB Receptor Agonist 7,8-Dihydroxyflavone and Its Therapeutic Potential for Traumatic Brain Injury15. Ceftriaxone Treatment of TBI Part V. Drugs for TBI Rehabilitation16. Memantine: A Safe and Tolerable NMDA Antagonist with Potential Benefits in Traumatic Brain Injury17. Interventional Drugs for TBI Rehabilitation of Cognitive Impairment: The Cholinesterase Inhibitor Rivastigmine18. Docosahexaenoic Acid and Omega 3 Fatty Acids19. Treatment of Mood Disorders Following Traumatic Brain Injury